Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: The pan-american collaborative retina study
Purpose: To report the 24-month anatomic and Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (IVB) (Avastin; Genentech Inc., San Francisco, CA) (1.25 or 2.5 mg) in patients with subfoveal choroidal neovascularizat...
Autores Principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Artículo (Article) |
Lenguaje: | Inglés (English) |
Publicado: |
Elsevier Inc.
2010
|
Materias: | |
Acceso en línea: | https://repository.urosario.edu.co/handle/10336/22732 https://doi.org/10.1016/j.ophtha.2010.01.056 |